Wall Street analyst estimates for Tenaya Therapeutics, Inc. (TNYA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 2.05 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $2.0M | $2.5M | $4.0M | $8.7M | $8.7M | $8.5M | $8.4M |
| Gross Profit | -$2.0M | -$2.5M | -$4.0M | -$8.7M | -$8.7M | -$8.5M | -$8.4M |
| Research & Development | $23.1M | $31.1M | $54.4M | $94.5M | $98.0M | $86.7M | $68.6M |
| Selling, General & Admin | $4.6M | $5.3M | $14.4M | $22.4M | $24.5M | $20.7M | $24.7M |
| Operating Expenses | $27.7M | $36.4M | $68.8M | $116.9M | $122.5M | $107.5M | $84.9M |
| Operating Income | -$27.7M | -$38.9M | -$72.8M | -$125.6M | -$131.2M | -$115.9M | -$93.3M |
| EBITDA | -$25.7M | -$35.9M | -$68.7M | -$115.0M | -$115.4M | -$102.7M | -$82.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$26.2M | -$38.4M | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$25.8M | -$38.4M | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
| EPS | $-0.95 | $-0.93 | $-1.69 | $-2.76 | $-1.68 | $-1.31 | $-0.59 |
| EPS (Diluted) | $-0.95 | $-0.93 | $-1.69 | $-2.76 | $-1.68 | $-1.31 | $-0.59 |
| Shares Outstanding (Diluted) | $27.2M | $41.1M | $41.3M | $44.8M | $73.8M | $84.8M | $153.0M |
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of TNYA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks